GE Healthcare Licenses Genomic Biomarker for Lung Cancer from Insight Genetics  
5/31/2012 10:29:29 AM

ALISO VIEJO, Calif. and NASHVILLE, Tenn.--(BUSINESS WIRE)--Clarient Diagnostic Services, Inc., a GE Healthcare company, and molecular diagnostics company Insight Genetics, Inc., today announced a worldwide licensing agreement for intellectual property from Insight Genetics, granting Clarient rights to develop a genetic test covering the ALK (anaplastic lymphoma kinase) biomarker, a promising target for several classes of cancer drugs.